Page 141 - Read Online

Page 393 Santiago et al. J Transl Genet Genom 2021;5:380-95 https://dx.doi.org/10.20517/jtgg.2021.16

2017;102:118-29. DOI PubMed PMC
35. Alexander TB, Gu Z, Iacobucci I, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature
2018;562:373-9. DOI PubMed PMC
36. Fazio G, Bardini M, De Lorenzo P, et al. Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants.
Blood 2021;137:1980-4. DOI PubMed
37. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008;8:380-90. DOI
PubMed
38. Coustan-smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic
leukaemia. Lancet Oncol 2009;10:147-56. DOI PubMed PMC
39. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481:157-
63. DOI PubMed PMC
40. Patrick K, Wade R, Goulden N, et al. Outcome for children and young people with Early T-cell precursor acute lymphoblastic
leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol 2014;166:421-4. DOI PubMed
41. Wood BL, Winter SS, Dunsmore KP, et al. T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the
early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease
(MRD) in Children’s Oncology Group (COG) Study AALL0434. Blood 2014;124:1. DOI
42. Liu Y, Easton J, Shao Y, et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat
Genet 2017;49:1211-8. DOI PubMed PMC
43. Girardi T, Vicente C, Cools J, De Keersmaecker K. The genetics and molecular biology of T-ALL. Blood 2017;129:1113-23. DOI
PubMed PMC
44. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science
2004;306:269-71. DOI PubMed
45. Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest 2012;122:3398-406. DOI
PubMed PMC
46. Maude SL, Dolai S, Delgado-Martin C, et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell
precursor (ETP) acute lymphoblastic leukemia. Blood 2015;125:1759-67. DOI PubMed PMC
47. Neumann M, Coskun E, Fransecky L, et al. FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and
imply the clinical use of tyrosine kinase inhibitors. PLoS One 2013;8:e53190. DOI PubMed PMC
48. Waanders E, Gu Z, Dobson SM, et al. Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic
leukemia. Blood Cancer Discov 2020;1:96-111. DOI PubMed PMC
49. Ma X, Edmonson M, Yergeau D, et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic
leukaemia. Nat Commun 2015;6:6604. DOI PubMed PMC
50. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science
2008;322:1377-80. DOI PubMed PMC
51. Li B, Brady SW, Ma X, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
Blood 2020;135:41-55. DOI PubMed PMC
52. Schroeder MP, Bastian L, Eckert C, et al. Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies
subtype-specific cytokine and metabolic signatures. Sci Rep 2019;9:4188. DOI PubMed PMC
53. Li B, Li H, Bai Y, et al. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. Nat Med
2015;21:563-71. DOI PubMed PMC
54. Meyer JA, Wang J, Hogan LE, et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet
2013;45:290-4. DOI PubMed PMC
55. Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011;471:235-9.
DOI PubMed PMC
56. Treviño LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat
Genet 2009;41:1001-5. DOI PubMed PMC
57. Whitlock JA. Down syndrome and acute lymphoblastic leukaemia. Br J Haematol 2006;135:595-602. DOI PubMed
58. Ripperger T, Schlegelberger B. Acute lymphoblastic leukemia and lymphoma in the context of constitutional mismatch repair
deficiency syndrome. Eur J Med Genet 2016;59:133-42. DOI PubMed
59. Brown AL, de Smith AJ, Gant VU, et al. Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood
2019;134:1227-37. DOI PubMed PMC
60. Maloney KW, Carroll WL, Carroll AJ, et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of
sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood 2010;116:1045-
50. DOI PubMed PMC
61. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated
acute lymphoblastic leukemia. Nat Genet 2009;41:1243-6. DOI PubMed PMC
62. Rabin KR, Devidas M, Chen Z, et al. Outcomes of patients with Down syndrome and CRLF2 -overexpressing acute lymphoblastic
leukemia (ALL): a report from the Children's Oncology Group (COG). Blood 2020;136:44-5. DOI
63. Gocho Y, Yang JJ. Genetic defects in hematopoietic transcription factors and predisposition to acute lymphoblastic leukemia. Blood
2019;134:793-7. DOI PubMed PMC
64. Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet